CYNK-001
- Generic Name
- CYNK-001
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
- Associated Conditions
- -
- Associated Therapies
- -
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 27
- Registration Number
- NCT04310592
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath